This study is testing if a drug called fezolinetant can help reduce moderate to severe hot flashes (vasomotor symptoms or VMS) in women with early-stage breast cancer (Stage 1-3) who are currently taking endocrine therapy like tamoxifen or aromatase inhibitors. You might be eligible if you are 18 or older, have HR+ breast cancer, and are on endocrine therapy. The study will compare fezolinetant to a placebo (an inactive pill) over 12 weeks. Researchers will consider the treatment successful if fezolinetant significantly reduces the frequency of moderate/severe hot flashes compared to the placebo group. The study plans to enroll 92 participants.

Study design

This is a Phase 2, randomized, double-blinded, placebo-controlled study involving 92 participants. Participants will be randomly assigned to receive either fezolinetant or a placebo.

What's involved

You would take either fezolinetant or a placebo pill once daily for 12 weeks. You will also record daily information about your hot flashes.

Compensation

Not stated in the trial record.

Follow-up

After the 12-week treatment period, your hot flashes will be formally assessed. You will then be told which treatment you received and can choose to switch if you wish.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.